中国药科大学学报2024，Vol.55Issue(2)：167-180,14.DOI:10.11665/j.issn.1000-5048.2023080103
降尿酸化合物的活性评价方法研究进展
Recent advances in bioactivity evaluation methods of uric acid-lowering compounds
摘要
Abstract
Hyperuricemia is a metabolic disease caused by elevated uric acid in the body,and is closely related to the increased risk of cardiovascular disease,metabolic disorders,and renal complications.In the development process of uric acid-lowering drugs,activity evaluation is a crucial step.At present,the activity screening methods of uric acid-lowering drugs can be roughly divided into two categories:in vitro and in vivo.In vitro screening is mainly for such targets as xanthine oxidase,urate transporters,and purine nucleoside phosphorylase,etc.;while in vivo screening is achieved by rodent,poultry and organoid models.In this article,the activity evaluation methods for uric acid-lowering compounds are comprehensively summarized both in vitro and in vivo,aiming to provide some insight for the development of uric acid-lowering drugs.关键词
高尿酸血症/痛风/降尿酸/活性评价/药物研发Key words
hyperuricemia/gout/uric acid lowering/activity evaluation/drug discovery分类
化学化工引用本文复制引用
祁丹辉,史晓雨,刘新泳,展鹏..降尿酸化合物的活性评价方法研究进展[J].中国药科大学学报,2024,55(2):167-180,14.基金项目
This study was supported by Science Foundation for Outstanding Young Scholars of Shandong Province(No.ZR2020JQ31) 山东省杰出青年科学基金项目(No.ZR2020JQ31) （No.ZR2020JQ31）
